Schizophrenia drug Cobenfy could treat Alzheimer’s

Bristol Myers Squibb’s Cobenfy: A Potential Game-Changer in Alzheimer’s Treatment

Bristol Myers Squibb has high hopes for its newly approved schizophrenia drug, Cobenfy, which the company believes could generate billions of dollars in revenue. The drug has multibillion-dollar potential in various treatment areas, including Alzheimer’s disease psychosis, Alzheimer’s agitation, and Alzheimer’s cognition, bipolar disease, and autism. However, Alzheimer’s is the largest market for Cobenfy, with nearly 6 million patients in the US and around half of them experiencing psychosis.

A New Treatment for Alzheimer’s-Related Psychosis

Cobenfy could be the first drug specifically approved for Alzheimer’s-related psychosis, a condition that is often treated with atypical antipsychotics, which can increase the risk of death. Cobenfy, on the other hand, does not pose the same risk.

Breaking Down the Numbers

The company plans to release initial late-stage trial data for Cobenfy in Alzheimer’s-related psychosis treatment later this year and expects to start phase three trials in Alzheimer’s agitation, Alzheimer’s cognition, and bipolar disorder in 2025. Studies in autism will begin in 2026.

JPMorgan analyst Chris Schott expects Cobenfy sales to reach around $5 billion by 2030, with a peak sales potential in the $10 billion range across multiple treatment uses.

A Full-Circle Moment for Cobenfy

Cobenfy’s development has come full circle, from its origins in treating Alzheimer’s to its approval for schizophrenia. The drug was developed from xanomeline, which was originally tested in the 1990s to reduce cognitive decline, but was shelved due to severe side effects. Bristol Myers Squibb’s acquisition of Karuna Therapeutics, where the drug was developed, has brought new hope to the treatment of Alzheimer’s.

Conclusion

Cobenfy has the potential to be a game-changer in the treatment of Alzheimer’s, particularly in addressing psychosis and agitation symptoms. With its multibillion-dollar potential, Cobenfy could bring significant revenue to Bristol Myers Squibb and improve the lives of millions of patients and their caregivers.

FAQs

Q: What is Cobenfy?
A: Cobenfy is a newly approved schizophrenia drug that has multibillion-dollar potential in various treatment areas, including Alzheimer’s disease psychosis, Alzheimer’s agitation, and Alzheimer’s cognition, bipolar disease, and autism.

Q: What is the largest market for Cobenfy?
A: The largest market for Cobenfy is Alzheimer’s, with nearly 6 million patients in the US and around half of them experiencing psychosis.

Q: What is the difference between Cobenfy and atypical antipsychotics?
A: Cobenfy does not increase the risk of death, unlike atypical antipsychotics, which are often used to treat psychosis in Alzheimer’s patients.